Pre-Money Valuation of JPY9 Billion is Approximately Multiples of Current Parent Company Market Capitalization.Strategic Investors Further Validation of Technology and Growth Potential.Further Commercialization with Recent 25,000 Unit Order from B2B Sales Channel. TOKYO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ:MRM) announces that its subsidiary MEDIROM MOTHER Labs Inc. raised to date an aggregate total of 260.3 million yen (approximtaely USD $ [1.7] million calculated ...

TOKYO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), “MEDIROM”, a holistic healthcare company that operates over 300 wellness salons across Japan and provides healthcare services, today announced the closing of its public offering of 2,860,000 American Depositary Shares at a public offering price of $1.75 per share, for gross proceeds of approximately $5,000,000 before deducting underwriting discounts and offering expenses. In addition, MEDIROM has granted the underwr ...

TOKYO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”) announces that two senior executives, Issei Homan, Chief Technology Officer of MEDIROM MOTHER Labs Inc. (“Mother Labs”), a subsidiary of MEDIROM, and Yasuhiro Hayami, Chief Business Officer of Mother Labs, invested in Mother Labs’ Series A financing at a pre-money valuation of of JPY9 billion (as of December 1, 2024, approximately USD $59,000,000). Messrs. Homan and Hayami are committed s ...

Company Overview - MEDIROM Healthcare Technologies Inc. is involved in health-tech and has announced participation from M3, Inc. in its Series A equity financing round for its subsidiary, MEDIROM MOTHER Labs Inc. [1] - The Series A financing round is led by NFES Technologies Inc. with a pre-money valuation of JPY 9 billion [1] MOTHER Labs and Product Offering - MEDIROM MOTHER Labs focuses on health-tech, offering the "Specific Health Guidance Program" through the "Lav" health application and developing the 24/7 recharge-free MOTHER Bracelet smart tracker [5] - The MOTHER Bracelet is notable for being the world's first 24/7 recharge-free smart tracker, utilizing innovative technology to generate power from temperature differences [7] - The device records five basic health metrics: heart rate, calories burned, body surface temperature, step count, and sleep [7] M3, Inc. Background - M3, Inc. operates a global physician platform and is recognized for its significant member panel, which includes over 330,000 Japanese and more than 6.5 million global physicians [4]

TOKYO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) ("Medirom" or the "Company") is pleased to announce that it is capitalizing on its extensive experience operating wellness clinics and healthcare technology to expand into the rehabilitation industry. In doing so, MEDIROM established a wholly-owned subsidiary, MEDIROM Rehab Solutions Inc., which acquired all of the rehabilitation centers of Y's, Inc. Prior to the acquisition by MEDIROM Rehab Solutions Inc., Y's, Inc. ...

TOKYO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; CEO: Koji Eguchi; listed on Nasdaq, NASDAQ: MRM; hereinafter "MEDIROM") announces that its subsidiary MEDIROM MOTHER Labs Inc. (Headquarters: Minato-ku, Tokyo; CEO: Yoshio Uekusa; hereinafter "MOTHER Labs"), has formed a capital and business alliance with NFES Technologies Inc. (Headquarters: Matsue City, Shimane Prefecture; CEO: Keita Adachi; hereinafter "NFES Group"), a subsidiary of NFES Inc. (H ...

TOKYO, July 22, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. ("we", "our", "us" or "the Company") hereby announces that its subsidiary MEDIROM Rehab Solutions Inc. entered into an agreement to purchase a rehabilitation business from Y's, Inc., a Japanese corporation, as of July 10, 2024. Y`s, Inc. operates 10 rehabilitation facilities around Tokyo for survivors of cerebral infarction, a type of stroke, and the company does business with major private, public and university hospitals in Japa ...

TOKYO, July 22, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. ("we", "our", "us" or "the Company") hereby announces that its subsidiary MEDIROM Rehab Solutions Inc. entered into an agreement to purchase a rehabilitation business from Y's, Inc., a Japanese corporation, as of July 10, 2024. Y`s, Inc. operates 10 rehabilitation facilities around Tokyo for survivors of cerebral infarction, a type of stroke, and the company does business with major private, public and university hospitals in Japa ...

Core Viewpoint - MEDIROM Healthcare Technologies Inc. plans to acquire a majority stake (70%) in Japan Gene Medicine Corporation, with an option to acquire the remaining 30% in the future, aiming to expand its presence in the healthcare technology sector in Japan [1][2]. Transaction Overview - The acquisition involves a share transfer agreement to acquire 70% of Japan Gene Medicine from an individual shareholder, with a legally binding memorandum for the option to acquire the remaining shares [1][2]. - The total transfer consideration is set at 2 billion yen, based on an enterprise value calculated using a multiplier of six times the adjusted EBITDA [8][18]. Market Context - Prenatal genetic testing services are underutilized in Japan, with only 7.2% of pregnant women using such services in 2016, indicating significant growth potential in this market [2]. - The demographic trends in Japan, such as an increasing childbearing age and declining birthrate, suggest a rising demand for genetic testing and analysis services [15]. Strategic Fit - The acquisition aligns with the company's strategic objective to become a holistic healthcare provider, enhancing its portfolio that includes health tech solutions like the "Lav®" training app and the "MOTHER Bracelet®" [2][16]. - Japan Gene Medicine's target demographic aligns with the company's wellness salon business, Re.Ra.Ku®, allowing for expanded service offerings and improved customer experience [16]. Financial Structure - The transaction will be financed through the company's own funds and borrowings, with a special purpose company established to facilitate the share transfer [5][19]. - The closing of the share transfer is contingent upon several conditions, including revised subcontracting agreements and financing commitments [19].

TOKYO, July 01, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ:MRM) ("Medirom" or the "Company"), a holistic healthcare company based in Japan, announced that on June 20th the Company was one of four Nasdaq listed Japanese companies that presented at the NASDAQ JAPAN IR EVENT 2024 at Nasdaq's U.S. headquarters. The Nasdaq event aimed to increase the presence of Japanese companies in the U.S. Four Japanese companies listed on Nasdaq presented to over 120 investors and media. Joseph Bra ...